Follow WOWNEWS 24x7 on:
Dr Reddy’s Laboratories Ltd, a leading global pharmaceutical company, has achieved a major milestone with its AVT03 biosimilar candidate, receiving an exclusive license for commercialization in the United States and a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). This advancement brings Dr Reddy’s closer to launching a highly anticipated biosimilar version of denosumab, a blockbuster drug used in osteoporosis and bone-related conditions, expanding access to affordable treatments in regulated markets.
Key Highlights on Dr Reddy’s AVT03 Biosimilar Journey
Dr Reddy’s holds exclusive commercial rights in the US for AVT03, developed by global biotech firm Alvotech, while jointly holding semi-exclusive rights in Europe and the United Kingdom.
The CHMP’s positive opinion recommends approval for AVT03 as a biosimilar to Amgen’s Prolia® and Xgeva®, medicines used to treat osteoporosis, prevent fractures, and manage skeletal complications in cancer patients.
The approval recommendation follows rigorous regulatory review, with final decision pending from the European Commission. The US Food and Drug Administration (FDA) has already accepted the biologics licensing application (BLA) for AVT03.
AVT03 will be supplied in user-friendly formats including a single-dose prefilled syringe (60 mg) and a single-dose vial (120 mg), matching the reference product’s pharmacological profile.
The collaboration leverages Dr Reddy’s extensive commercial infrastructure and regulatory expertise alongside Alvotech’s proven biosimilar development and manufacturing capabilities.
Strategic Importance of AVT03 for Dr Reddy’s
With the patent expiry of denosumab approaching, AVT03 represents a strategically important addition to Dr Reddy’s growing biosimilars portfolio targeted at highly regulated markets. The drug addresses substantial unmet needs in bone health, offering a more affordable alternative for patients suffering from osteoporosis and cancer-related bone complications.
Dr Reddy’s ability to commercialize AVT03 independently in the US enhances its footprint in the lucrative North American biosimilar market, while semi-exclusive access in Europe and the UK ensures broad patient access across major pharmaceutical markets.
Market Potential and Patient Benefits
Osteoporosis affects millions globally, particularly postmenopausal women at high risk of fractures, making Prolia one of the highest-selling biologics worldwide.
Xgeva’s role in preventing skeletal-related events in cancer patients adds a critical dimension to AVT03’s therapeutic impact.
Biosimilars like AVT03 can reduce healthcare costs significantly, improving treatment affordability and patient outcomes.
Dr Reddy’s commitment to biosimilars expands treatment options, fostering competition and accessibility in controlled pharmaceutical markets.
Regulatory Pathway and Future Outlook
The CHMP’s positive recommendation is a pivotal step toward European authorization of AVT03, anticipated in the coming months.
The FDA’s acceptance of the BLA indicates ongoing progress toward US market entry, expected to expand Dr Reddy’s biosimilar footprint substantially.
By combining Alvotech’s development acumen with Dr Reddy’s commercialization strength, AVT03 is poised for timely market launch and commercial success.
Conclusion: Dr Reddy’s Advances Biosimilar Leadership with AVT03’s Regulatory Milestones
Dr Reddy’s Laboratories’ exclusive US rights and the European CHMP’s positive opinion for AVT03 mark a breakthrough in the company’s biosimilar strategy. This collaboration bridges cutting-edge biosimilar technology and global commercialization expertise, enabling affordable access to critical bone health therapies. As AVT03 moves closer to regulatory approvals, Dr Reddy’s reinforces its position as a leading biosimilars innovator committed to transforming patient care across international markets.
Sources: GlobeNewswire, EMA, FDA, Dr Reddy’s Laboratories official releases, Economic Times, Moneycontrol
Please get more news India Glycols Doubles the Buzz: 1 Share Turns Into 2, Is This The Next Big Market Move?
Follow WOWNEWS 24x7 on:
Copyright 2024 WOWNEWS 24x7. All rights reserved. The WOWNEWS 24x7 is not responsible for the content of external sites. Read about our approach to external linking.
Powered By Just Imagine
